跳轉至內容
Merck
全部照片(1)

文件

T0318

Sigma-Aldrich

曲尼司特

≥98% (HPLC), powder

同義詞:

2-[[3-(3,4-二甲氧基苯基)-1-氧代-2-丙烯基] 氨基] 苯甲酸, 3,4-DAA, N-(3,4-二甲氧基肉桂酰)邻氨基苯甲酸, SB-252218, 利喘平

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C18H17NO5
CAS號碼:
分子量::
327.33
MDL號碼:
分類程式碼代碼:
41106500
PubChem物質ID:
NACRES:
NA.77

品質等級

化驗

≥98% (HPLC)

形狀

powder

顏色

white to beige

mp

166.2-168.2 °C (lit.)

溶解度

DMSO: >10 mg/mL
H2O: insoluble

起源

Kissei

儲存溫度

2-8°C

SMILES 字串

COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC

InChI

1S/C18H17NO5/c1-23-15-9-7-12(11-16(15)24-2)8-10-17(20)19-14-6-4-3-5-13(14)18(21)22/h3-11H,1-2H3,(H,19,20)(H,21,22)/b10-8+

InChI 密鑰

NZHGWWWHIYHZNX-CSKARUKUSA-N

基因資訊

應用

在小鼠骨髓来源的肥大细胞中研究了曲尼司特对肥大细胞表面受体的作用。

生化/生理作用

曲尼司特是一种抗哮喘药物,可抑制刺激单核细胞 LTC 4 和 PGE 2 的形成,但不抑制环氧合酶或脂氧合酶活性;抑制肥大细胞脱颗粒;在体内抑制 VEGF 诱导的血管生成 ,在体外也抑制人内皮细胞的增殖和管道形成 。曲尼司特可能代表一类新的治疗 T H 1 介导的自身免疫性疾病的药物。
曲尼司特还通过抑制细胞周期蛋白依赖性激酶抑制剂-1(p21Waf1 / Cip1)来抑制血管平滑肌细胞的增殖,它可用于治疗心脏同种异体移植物血管病变(cardiac allograft vasculopathy)。它用于治疗肥厚性瘢痕和瘢痕疙瘩。曲尼司特会抑制肿瘤坏死因子(TNF-α和TGF-β2),从而阻碍人视网膜色素上皮细胞系(ARPE)的上皮间质转化。

特點和優勢

该化合物由 Kissei 开发。要浏览其他制药公司开发的化合物列表批准的药物/候选药物的列表, 点击这里

象形圖

Exclamation mark

訊號詞

Warning

危險聲明

危險分類

Acute Tox. 4 Oral

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

個人防護裝備

dust mask type N95 (US), Eyeshields, Gloves


分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號,寫有 ‘Lot’或‘Batch’.。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Kaname Uno et al.
Journal of clinical gastroenterology, 46(9), e76-e82 (2012-09-08)
As circumferential or near-circumferential endoscopic submucosal dissection (ESD) for superficial esophageal neoplasms might evoke refractory strictures, multiple sessions of endoscopic balloon dilation (EBD) are required. We aimed to assess the effectiveness and safety of oral agent tranilast with EBD for
Md Soriful Islam et al.
The Journal of clinical endocrinology and metabolism, 99(5), E775-E785 (2014-03-13)
Uterine leiomyomas are highly prevalent benign tumors of premenopausal women and the most common indication for hysterectomy. However, the exact etiology of this tumor is not fully understood. The objective of the study was to evaluate the role of activin-A
Venkateswaran Subramaniam et al.
Experimental and molecular pathology, 90(1), 116-122 (2010-11-03)
In the treatment of breast cancer, although a wide of choice of drugs and treatment modalities are available, drug resistance or drug toxicity poses a considerable challenge. Tranilast is a well tolerated drug used in the treatment of allergic disorders.
Md Imran Khan et al.
PloS one, 14(5), e0216427-e0216427 (2019-05-10)
In this report, using NMR and molecular modeling, we have studied the structure of lysozyme-S100A6 complex and the influence of tranilast [N-(3, 4-dimethoxycinnamoyl) anthranilic acid], an antiallergic drug which binds to lysozyme, on lysozyme-S100A6 and S100A6-RAGE complex formation and, finally
Natsuko Kageyama-Yahara et al.
FEBS letters, 584(1), 111-118 (2009-11-12)
Mast cell activation by immunoglobulin E (IgE)-mediated stimuli is a central event in the pathogenesis of allergic disorders. The present report shows that treatment with pentagalloylglucose (PGG) resulted in a down-regulation of FcepsilonRI surface expression on mucosal-type murine bone marrow-derived

文章

Discover Bioactive Small Molecules for Lipid Signaling Research

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務